Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S. investments in research and manufacturing, according to CNBC. In the company's first-quarter earnings call,

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an interview that there’s room for other products as more doctors become aware of the disease and patients get diagnosed earlier. Read more.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.